Crinetics Pharmaceuticals shares rise as analysts see 'drug hunters in their zone'
Shares of Crinetics Pharmaceuticals Inc. (CRNX) gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an outperform rating, calling Crinetics 'drug hunters in their zone.' Crinetics focuses on developing treatments for rare endocrine diseaess, an area where current drugs' risk-benefit tradeoffs "leave much room for improvement, or approved options are outright lacking," the analysts wrote in a note Wednesday. Through its non-peptide drug discovery capability, Crinetics is well positioned to meaningfully improve treatments for a growing number of endocrine disorders, the analysts wrote, and the company's investigational treatment paltusotine is on track to become the preferred therapy for acromegaly, a serious disease in which the body produces too much growth hormone. The Oppenheimer analysts have a $40 price target for the shares. Crinetics stock is down 9.7% in the year to date, while the S&P 500 has gained 17.6%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-31-23 0807ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters